Qiming Venture Partners USA is a venture capital firm that invests in early-stage healthcare and technology companies in the United States.

Qiming Venture Partners USA

We know how companies can and should be built.

Founded in 2017, Qiming Venture Partners USA is a healthcare venture capital firm and healthcare investor with a combination of deep technical expertise that allows us to identify tomorrow’s innovations early and strong operational experience with a hands-on approach that makes us the investor of choice for early-stage biotech companies.

Our partners often are sought-after to be on company boards because of their proven, hands-on approach to supporting CEOs and scaling operations. They are trusted business and thought partners.

All of our partners have worked and lived outside of the US, providing us with a true global mindset and our networks are extensive. Only Qiming Venture Partners USA can offer exclusive access and synergy to China, the second-largest healthcare market in the world. We have a unique ability to leverage a world-class China and broader Asian network for market diligence, deal flow, and operational support for portfolio companies.

We harness the deep and highly accretive backgrounds and skillsets of our founders with a next-generation approach through our partners to understand tomorrow’s innovations and reaching across a wide variety of crossover and public investors.

Elevation Oncology

Satellos Bioscience

Talaris Therapeutics

Ventyx Biosciences

HilleVax

Icosavax

Jasper Therapeutics

Congratulations to Umoja Biopharma on their groundbreaking partnership with AbbVie to advance development of in vivo CAR-T therapies for patients in need.

Umoja's VivoVec + RACR/CAR technology enables CAR-T transduction to occur directly in the patient while avoiding challenging chemotherapeutic lymphodepletion regimens, overcoming sizable patient access + manufacturing challenges faced with autologous CAR-T therapies, which are created outside the body. 

Today, we are one significant step closer to a world where more patients, in a safer manner, could be eligible to receive potentially disease-curative medicines. This is made possible by Umoja's outstanding drug development expertise and catalyzed by their state of the art manufacturing capabilities at the CLIMB.

Hearty congrats to the Icosavax, Inc. team on positive data for bivalent RSV / hMPV vaccine and subsequent transaction to AstraZeneca!

https://lnkd.in/gv_x9cZU

Metric
Company Name	Qiming Venture Partners USA
Symbol
MSH ID	COM:QIMINGVCUSA
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital
Country	US
Stage
Employee Count
Website	qimingvcusa.com
LinkedIn	qiming-venture-partners-usa
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:QIMINGVCUSA

Qiming Venture Partners USA

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue